聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的效果观察  

Effect observation of Pegylated Interferon combined with Ribavirin in the treatment of chronic hepatitis C

作　　者：陈静[1] 方亮[1] 

机构地区：[1]广州市第一人民医院,广东广州510180

出　　处：《中国当代医药》2013年第13期71-72,共2页China Modern Medicine

摘　　要：目的探讨聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎患者的效果。方法选择本院2008年6月～2011年6月收治的慢性丙型肝炎患者100例,随机分为治疗组和对照组,每组50例,治疗组患者给予聚乙二醇干扰素联合利巴韦林治疗,对照组患者给予重组人干扰素α2b注射液联合利巴韦林治疗。观察两组患者持续应答率,统计两组患者实际临床疗效。结果治疗组持续应答率为88.0%,对照组持续应答率为42.0%。结论慢性丙型肝炎患者采用聚乙二醇干扰素联合利巴韦林治疗的疗效显著,值得临床推广应用。Objective To explore the effects of Pegylated Interferon combined with Ribavirin in treatment of patients with chronic hepatitis C. Methods One hundred patients suffering from chronic hepatitis C admitted into our hospital from June 2008 to June 2011 were evenly divided into treatment group and control group randomly, with 50 cases in each group. In the treatment group, patients were provided with Pegylated Interferon with Ribavirin, while in the control group, participants were treated by human recombinant interferon alpha 2b injection with Ribavirin. The sustained virological response （SVR） rate and clinical effects in the two groups were calculated and observed. Results The SVR rate in the treatment group was 88.0%, while that in control group was 42.0%. Conclusion Application of Pegylated Interferon combined with Ribavirin in the treatment of chronic hepatitis C patients can obtain a remarkable effect, which is worthy of extension in clinic.

关 键 词：慢性丙型肝炎 聚乙二醇干扰素 利巴韦林 疗效 持续应答率 

分 类 号：R512.6[医药卫生—内科学]